- Home
- BIVI vs PMN Comparison
BIVI vs PMN Comparison
Compare BIVI & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- PMN
- Stock Information
- Founded
- BIVI 2013
- PMN 2004
- Country
- BIVI United States
- PMN Canada
- Employees
- BIVI N/A
- PMN N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- PMN Pharmaceuticals and Biotechnology
- Sector
- BIVI Health Care
- PMN Health Care
- Exchange
- BIVI Nasdaq
- PMN Nasdaq
- Market Cap
- BIVI 15.0M
- PMN 16.0M
- IPO Year
- BIVI N/A
- PMN N/A
- Fundamental
- Price
- BIVI $6.03
- PMN $0.77
- Analyst Decision
- BIVI
- PMN Strong Buy
- Analyst Count
- BIVI 0
- PMN 3
- Target Price
- BIVI N/A
- PMN $4.33
- AVG Volume (30 Days)
- BIVI 66.5K
- PMN 21.3M
- Earning Date
- BIVI 09-29-2025
- PMN 08-11-2025
- Dividend Yield
- BIVI N/A
- PMN N/A
- EPS Growth
- BIVI N/A
- PMN N/A
- EPS
- BIVI N/A
- PMN N/A
- Revenue
- BIVI N/A
- PMN N/A
- Revenue This Year
- BIVI N/A
- PMN N/A
- Revenue Next Year
- BIVI N/A
- PMN N/A
- P/E Ratio
- BIVI N/A
- PMN N/A
- Revenue Growth
- BIVI N/A
- PMN N/A
- 52 Week Low
- BIVI $5.74
- PMN $0.38
- 52 Week High
- BIVI $75.00
- PMN $1.59
- Technical
- Relative Strength Index (RSI)
- BIVI 34.02
- PMN 54.99
- Support Level
- BIVI $7.24
- PMN $0.77
- Resistance Level
- BIVI $7.75
- PMN $1.06
- Average True Range (ATR)
- BIVI 0.72
- PMN 0.16
- MACD
- BIVI -0.10
- PMN 0.01
- Stochastic Oscillator
- BIVI 8.78
- PMN 30.80
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.